AXA1125

AXA1125 or LIVRQNac is a new drug developed by Axcella Therapeutics which is currently in clinical trials for post-exertional fatigue caused by Long COVID. AXA1125 has been described as a "novel composition of amino acids" and a "metabolic modulator" and consists of five amino acids (arginine, glutamine, isoleucine, leucine, and valine) and N-acetylcysteine (NAC).

Amino acids and precusors

 * arginine
 * glutamine
 * isoleucine
 * leucine
 * valine
 * N-acetylcysteine (NAC)

Learn more

 * Oxford test potential treatment for fatigue in long COVID patients - Oxford University
 * Poster: Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers - Axcella Health Inc.